Vitamin D, skin cancer and all-cause mortality
|
|
- August Bradford
- 6 years ago
- Views:
Transcription
1 Vitamin D, skin cancer and all-cause mortality 3rd International UV and Skin Cancer Prevention Conference - Melbourne 2015 Sara Gandini, PhD Senior staff scientist Vice-director Division of Epidemiology and Biostatistics European Institute of Oncology - Milan, Italy
2 Outline Vitamin D, Cutaneous Melanoma (CM) and Non Melanoma Skin Cancer (NMSC) risk: - Serum level of 25(OH)D - Vitamin D receptors (VDR) polymorphisms - Vitamin D supplementation Sun exposure, Vitamin D and CM Disease Free Survival (DFS) Vitamin D and overall and cancer mortality
3 Meta-analysis: 25(OH)D and VDR and skin cancer risk First author, PY, cancer Asgari, 2010, BCC Eide, 2011, BCC Liang 1, 2012, BCC Liang 1, 2012, BCC van der Pols, 2013, BCC Summary RR for BCC= 1.82 (1.38, 2.40) I 2 =0% Liang 1, 2012, SCC Liang 1, 2012, SCC Eide, 2011, SCC van der Pols, 2013, SCC Summary RR for SCC= 1.68 (0.44, 6.39) I 2 =81% Tang, 2010, NMSC Afzal, 2013, NMSC Summary RR for NMSC= 1.64 (1.02, 2.65) I 2 =81% Nürnberg, 2009, CM Afzal, 2013, CM van der Pols, 2013, CM Major, 2012, CM Summary RR for CM = 1.46 (0.60, 3.53) 1,420 CM and 2,317 NMSC I 2 =54% Not surprising: the main source of vitamin D is sun exposure Caini S et al. Eur J Ca BsmI and FokI polymorphisms are associated with skin cancer risk Serrano D. et al. Eur J Cancer Prev Gnagnarella P. et al. Carcinogenesis Raimondi S. et al. Mutation Research, 2014.
4 Vitamin D supplementation and CM risk: WHI trial WHI trial Tang J Y et al. JCO Giovannucci. N Engl J Med Overall no effect. BUT Vitamin D+cal. vs placebo: HR=0.43 ( ) P interaction= 0.04 in women with history of NMSC History of NMSC associated with increased risk of CM. The trial was criticized for the too low dose vitamin D, the low adherence of women to supplementation.
5 Outline Vitamin D and CM risk: - Serum level of 25(OH)D - Vitamin D receptors polymorphisms - Vitamin D supplementation Sun exposure, Vitamin D and melanoma DFS Vitamin D and overall and cancer mortality
6 Cumulative Incidence Cumulative Incidence Sunny holidays and DFS in CM pts Cohort of 691 CM pts (median fu-p 4 y) Sunny holidays during f-up associated with reduced DFS. Not sunbed use or exposure during hot hours. 0.3 No sunny holidays Sunny holidays At diagnosis 0.3 No sunny holidays Sunny holidays During follow-up 0.2 Cox model P=0.16 HR=4.55; 95% CI ( ) P= HR=0.30 (0.10, 0.87) P=0.03 adjusted for age, gender, education, Breslow, ulceration and MD degree Cox model P=0.03 HR=0.27 (95%CI: ) Years Competing risk framework for N0M0 pts Gandini S. et al. Plos One At time of questionnaire Years 2 vs 0 weeks: HR=0.74 (95%CI: 0.16, 3.45) >2 vs 0 weeks: HR=0.28 (95%CI: 0.08, 0.98) P for trend =0.04
7 Change in 25(OH)D and DFS in CM pts Change in 25OHD in nmol/l HR (95%CI) < (1.36, 2.76) <5.30 to (0.85, 1.78) to 4.6: 1.00 >4.6: 1.61 (1.14, 2.28) Adj for stage, age, sex, BMI In a cohort of 1171 CM pts change in 25(OH)D in 1 year during follow-up was associated with DFS: very low and very high level may increase risk of relapse Saiag et al. JNCI 2015
8 MelaViD: No-profit multicenter randomized double blind phase III trial In Italy the incidence of CM has almost doubled in the last 10 years. For Stage II CM no standard treatment is available and the OS at 5 year is 70% Stage II melanoma n=878 R Main endpoint: DFS Sequential trial design with 3 planed interim analyses. Scientific PI: Gandini S. Preliminary analysis at baseline VD IU in average per day Placebo 3 years Seasons n. pts Median* Q1 Q3 August-November December-March April-July Total * 25(OH)D> 30ng/ml Gandini et al Int. J. Cancer F-up 2 years
9 Outline Vitamin D and CM risk: - Serum level of 25(OH)D - Vitamin D receptors polymorphisms - Vitamin D supplementation Sun exposure, Vitamin D and melanoma outcome Vitamin D and overall and cancer mortality
10 I 2 =0 The reduction was 8% for studies for which the intervention was at least 3 years and for those studies with a placebo control group. Autier and Gandini. Arch. Int. Med Meta-Analysis on VD and overall mortality The 18 RCTs included generally healthy people, at high risk for fractures.
11 Zitterman, Gandini et al. Am J Clin Nutr 2011 top quintile as reference Schöttker et al. BMI 2014 Meta-analysis and Pooled-analysis on 25(OH)D and overall mortality and cancer mortality Meta-analysis of 11 prospective cohort studies: 5,341 died for any cause Pooled-analysis of 7 prospective cohort studies: 2,227 died of cancer 30% (20%-40%) mortality reduction for an increase of 20 ng/ml of 25(OH)D
12 RCTs: vitamin D supplementation and cancer mortality RR=1.00 (0.94, 1.06) for cancer incidence For cancer mortality: 1,180 deaths I 2 =0% Vitamin D 3 suppl (given singly) decreased cancer mortality and all-cause mortality. Risk of type I errors: low power Risk of attrition bias due to dropout of participants. The Cochrane Collaboration, 2014 Keum and Giovannucci. BJC 2014
13 Conclusions Some evidence that vitamin D may have a beneficial influence on: - Overall mortality - Cancer mortality - Melanoma recurrence/survival (vitamin D reduction during f-up) Mainly from observational studies and RCTs but with low statistical power, low dose and low adherence Properly designed randomized clinical trials are necessary to demonstrate the effect of vitamin D supplementation on melanoma outcome, cancer mortality and overall mortality
Sun exposure and indoor tanning and skin cancer
Reviews and Meta-analyses analyses of Sun exposure and indoor tanning and skin cancer Sara Gandini, PhD Division of Epidemiology and Biostatistics European Institute of Oncology - Milan, Italy Phenotypical
More informationVitamin D and Inflammation
Vitamin D and Inflammation Susan Harris, D.Sc. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University Boston, MA Vitamin D Liver 25(OH)D storage form nmol/l=ng/ml x 2.5 Renal 1,25(OH)
More informationObservational Studies vs. Randomized Controlled Trials
Observational Studies vs. Randomized Controlled Trials Edward Giovannucci, MD, ScD Harvard School of Public Health Harvard Medical School Boston MA 02115 (1)The relevance of observational data as compared
More informationFOR CONSUMERS AND PATIENTS
AVAILABILITY OF VITAMIN D FOR CONSUMERS AND PATIENTS Prof. Heike A. Bischoff-Ferrari, MD, DrPH Centre on Aging and Mobility, University of Zurich Dept. of Rheumatology, University Hospital Zurich Overview
More informationNutraceuticals and Cardiovascular Disease: Are we fishing?
Nutraceuticals and Cardiovascular Disease: Are we fishing? ACC Rockies 2013 March 20,2013 Sheri L. Koshman BScPharm, PharmD, ACPR Assistant Professor, Division of Cardiology, University of Alberta sheri.koshman@ualberta.ca
More informationVitamin D and Calcium Therapy: how much is enough
Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS
More informationThe Endocrine Society Guidelines
Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS
More informationResponse. Philippe Saiag, 1,2 Philippe Aegerter, 3,4,5 Mathieu Boniol 6, Boulogne-Billancourt, France.
Saiag, Philippe and Aegerter, Philippe and Boniol, Mathieu (2016) Response. Journal of the National Cancer Institute, 108 (4). ISSN 0027-8874, http://dx.doi.org/10.1093/jnci/djw015 This version is available
More informationNutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Objectives
Nutritional concepts for the prevention and treatment of osteoporosis: what, for whom, when? Bess Dawson-Hughes, MD Disclosures: Amgen, DSM, Nestle, Opko, Pfizer, Roche, Tricida Interrelationships of muscle
More informationSURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS
SURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS Everardo D. Saad, MD Medical Director, IDDI everardo.saad@iddi.com Acknowledgement to Marc Buyse 1 The ideal endpoint
More informationCalcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People
Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,
More informationSunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy
Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy Sara Gandini 1*, Esther De Vries 2, Giulio Tosti 3, Edoardo
More informationLeveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationAssociation of Prediagnostic Serum Vitamin D Levels with the Development of Basal Cell Carcinoma
ORIGINAL ARTICLE Association of Prediagnostic Serum Vitamin D Levels with the Development of Basal Cell Carcinoma Maryam M. Asgari 1,2, Jean Tang 3, Margaret E. Warton 1, Mary-Margaret Chren 2,4, Charles
More informationVitamin D Assay --> Policy History. Policy. Background. Additional Information. (
--> (https://www.aetna.com/) Vitamin D Assay Clinical Policy Bulletins Medical Clinical Policy Bulletins Number: 0945 Policy Aetna considers measurements of serum 25-hydroxyvitamin D experimental and investigational
More informationPrevention of cancer the influence of diet
Prevention of cancer the influence of diet Food Network, 2010 Anne Tjønneland Institut for Epidemiologisk Kræftforskning, Kræftens Bekæmpelse Risk of cancer Indien / USA Aldersspecifik brystkræftincidens
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationHow to Design, Conduct, and Analyze Vitamin D Clinical Trials
How to Design, Conduct, and Analyze Vitamin D Clinical Trials William B. Grant, PhD Sunlight, Nutrition and Health Research Center wbgrant@infionline.net Disclosure I receive funding from Bio-Tech Pharmacal,
More informationSunbed Use in Europe: Important Health Benefits and Minimal Health Risks
Sunbed Use in Europe: Important Health Benefits and Minimal Health Risks William B. Grant, Ph.D. Director Sunlight, Nutrition and Health Research Center, San Francisco Outline Health Benefits of UV exposure
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationSunscreens and cutaneous neoplasia:
Sunscreens and cutaneous neoplasia: Overview and update from the literature Catherine Olsen, Louise Wilson, Neela Biswas, Juhi Loyalka, David Whiteman Cancer Control Group QIMR Berghofer Medical Research
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationAlcohol & Cancer: from prevention to the patient
Alcohol & Cancer: from prevention to the patient -from consistency to inconsistencies- Ellen Kampman Wageningen University Academic Medical Centre St Radboud Nijmegen 23 september 2010 Alcohol and the
More informationSusan Steck, Ph.D., M.P.H., R.D.
Susan Steck, Ph.D., M.P.H., R.D. Associate Professor Department of Epidemiology and Biostatistics Cancer Prevention and Control Program Center for Research in Nutrition and Health Disparities Arnold School
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationHow to improve the reliability of Single Arm Trials
Workshop on Single Arm Trials in Oncology Products EMA, London, June 30, 2016 How to improve the reliability of Single Arm Trials Paolo Bruzzi Clinical Epidemiology Unit IRCCS San Martino-IST - National
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationTheories: Reduced Milk Consumption. Case of the A Family. Physiology of Vitamin D. Why Is Everyone Vitamin D Deficient?
Case of the A Family Theories: Reduced Milk Consumption Osama A. 51 y/o male from Sudan; 4 children Oldest son Ahmed, tears ACL Soccer Youngest Son, Osman, fx Ulna cross St Second Son, Ayman, Fx Tib/Fib
More informationVitamin D & Breast Cancer: New Research & Recommendations
Vitamin D & Breast Cancer: New Research & Recommendations JoEllen Welsh, PhD Empire Innovations Professor University at Albany Cancer Research Center Vitamin D Biology Pre-D3 7-dehydrocholesterol UV Cholecalciferol
More informationDisclosure Information Relationships Relevant to this Session
Disclosure Information Relationships Relevant to this Session DeCensi, Andrea No relevant relationships to disclose. Please note, all disclosures are reported as submitted to ASCO, and are always available
More informationSurgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
More informationHEALTH EFFECTS Biology Dr. Rüdiger Greinert Head of Dept. Mol. Cellbiology Skin Cancer Center Buxtehude/Elbeclinics Buxtehude
Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) Opinion on Biological effects of ultraviolet radiation relevant to health with particular reference to sunbeds for cosmetic purposes
More informationStatistical considerations in indirect comparisons and network meta-analysis
Statistical considerations in indirect comparisons and network meta-analysis Said Business School, Oxford, UK March 18-19, 2013 Cochrane Comparing Multiple Interventions Methods Group Oxford Training event,
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationPrevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano
Prevenzione secondaria dell ischemia cerebrale di origine arteriosa Marco Cattaneo Ospedale San Paolo Università degli Studi di Milano Cerebral Ischemia of Arterial Origin (CIAO) Cumulative meta-analysis
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationJoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH Brigham and Women's Hospital Harvard Medical School
The COcoa Supplement and Multivitamin Outcomes Study (COSMOS): A Randomized Trial of Cocoa Flavanols and Multivitamins in the Prevention of CVD and Cancer JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD,
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationOther potential bias. Isabelle Boutron French Cochrane Centre Bias Method Group University Paris Descartes
Other potential bias Isabelle Boutron French Cochrane Centre Bias Method Group University Paris Descartes 1 Outlines RoB tool for specific design Cross over trial Cluster randomized controlled trials Mono
More informationSupplementary Online Content
Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B
More informationVitamin D Deficiency
Learning Objectives Vitamin D Deficiency 1. Summarize the basics of Vitamin D metabolism 2. Identify who to screen for Vitamin D Deficiency 3. Assess when to recommend Vitamin D Supplementation 4. Recognize
More informationProtocol Development: The Guiding Light of Any Clinical Study
Protocol Development: The Guiding Light of Any Clinical Study Susan G. Fisher, Ph.D. Chair, Department of Clinical Sciences 1 Introduction Importance/ relevance/ gaps in knowledge Specific purpose of the
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationCONTENT SUPPLEMENTARY FIGURE E. INSTRUMENTAL VARIABLE ANALYSIS USING DESEASONALISED PLASMA 25-HYDROXYVITAMIN D. 7
CONTENT FIGURES 3 SUPPLEMENTARY FIGURE A. NUMBER OF PARTICIPANTS AND EVENTS IN THE OBSERVATIONAL AND GENETIC ANALYSES. 3 SUPPLEMENTARY FIGURE B. FLOWCHART SHOWING THE SELECTION PROCESS FOR DETERMINING
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationA Proposed Randomized Trial of Cocoa Flavanols and Multivitamins in the Prevention of Cardiovascular Disease and Cancer
A Proposed Randomized Trial of Cocoa Flavanols and Multivitamins in the Prevention of Cardiovascular Disease and Cancer JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH Brigham and Women's Hospital
More informationEmerging Areas Relating Vitamin D to Health
ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationThe Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
More informationModifiable Up-Stream Risk Factors:
Modifiable Up-Stream Risk Factors: Recent Studies in AF Prevention Behzad Pavri, MD, FACC, FHRS Professor of Medicine Director, CCEP Fellowship Thomas Jefferson University Hospital, Philadelphia, USA Disclosures
More informationIntroduction to Clinical Trials - Day 1 Session 2 - Screening Studies
Introduction to Clinical Trials - Day 1 Session 2 - Screening Studies Presented July 23, 2018 Susanne J. May Department of Biostatistics University of Washington Daniel L. Gillen Department of Statistics
More informationVitamin D in At-Risk Populations. Bonny Specker, PhD EA Martin Program in Human Nutrition South Dakota State University
Vitamin D in At-Risk Populations Bonny Specker, PhD EA Martin Program in Human Nutrition South Dakota State University Outline Introduction Factors Influencing Endogenous Synthesis of Vitamin D Sun exposure
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationWhat do dermatologists and patients need from topical formulations?
Dermatology and Topical Formulation 11:15-11:50 h What do dermatologists and patients need from topical formulations? Richard Weller University of Edinburgh, United Kingdom What do dermatologists and patients
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationLifestyle Risk Factors and Cancer Prevention
February 3-5, 2016 Lansdowne Resort, Leesburg, VA Lifestyle Risk Factors and Cancer Prevention Melinda L. Irwin, PhD, MPH Professor of Epidemiology, Yale School of Public Health, Associate Director (Population
More informationMOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators
MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators Thierry André, Armand de Gramont, Benoist Chibaudel, Annemilaï Raballand,
More informationEconomic Analyses of Nutrient Interventions for Chronic Disease Prevention Paul M. Coates, Ph.D. Director
Economic Analyses of Nutrient Interventions for Chronic Disease Prevention Paul M. Coates, Ph.D. Director Office of Dietary Supplements National Institutes of Health Overview What is the science telling
More informationSection Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD
Prevention of dementia Author Daniel Press, MD Michael Alexander, MD Section Editor Steven T DeKosky, MD, FAAN Kenneth E Schmader, MD Deputy Editor Janet L Wilterdink, MD Last literature review version
More informationV t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s
Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic
More informationSTUDY. Vitamin D and Nonmelanoma Skin Cancer in a Health Maintenance Organization Cohort
ONLINE FIRST STUDY Vitamin D and Nonmelanoma Skin Cancer in a Health Maintenance Organization Cohort Melody J. Eide, MD, MPH; Dayna A. Johnson, MSW, MPH; Gordon R. Jacobsen, MS; Richard J. Krajenta, BS;
More informationControversies in Clinical Trials
Controversies in Clinical Trials Christopher B Cooper, MD Professor of Medicine and Physiology David Geffen School of Medicine Medical Director, UCLA COPD Center Methodological issues discussed Pitfalls
More informationIs aspirin ready for colorectal cancer chemoprevention and adjuvant therapy?
Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy? Robert Benamouzig Service de Gastroentérologie Hôpital Avicenne Bobigny, France Aspirin and Colorectal carcinogenesis Aspirin
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationBenefits of Vitamin D for Cancer and Pregnancy/Birth Outcomes. William B. Grant, PhD Sunlight, Nutrition and Health Research Center, San Francisco
Benefits of Vitamin D for Cancer and Pregnancy/Birth Outcomes William B. Grant, PhD Sunlight, Nutrition and Health Research Center, San Francisco Disclosure I receive funding from Bio Tech Pharmacal, Inc.
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationLow-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers
Low-Fat Dietary Pattern Intervention Trials for the Prevention of Breast and Other Cancers Ross Prentice Fred Hutchinson Cancer Research Center and University of Washington AICR, November 5, 2009 Outline
More informationPhilippe AUTIER, MD, MPH
Philippe AUTIER, MD, MPH International Agency for Research on Cancer (IARC) 150 Cours Albert Thomas F-69372 Lyon Cedex 08, France Tel: +33-(0) 472 73 81 64 Email: autierp@iarc.fr March 2, 2006 Comments
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationImproving Outcomes from Colorectal Cancer: Diet, Lifestyle, and Chemoprevention
Improving Outcomes from Colorectal Cancer: Diet, Lifestyle, and Chemoprevention Kimmie Ng, MD, MPH Director of Clinical Research Director, GI Biobank and Biospecimen Research Gastrointestinal Cancer Center
More informationVITAMIN D. Christina Nieuwoudt RD(SA) CCSSA/SASPEN 2018
VITAMIN D Christina Nieuwoudt RD(SA) CCSSA/SASPEN 2018 1 OBJECTIVES Why is it in the spotlight? Vit D and acute illness If it has a role how much should we give? Future 2 Why is it in the spotlight? FUNCTIONS
More informationEnclosed you will find our revised manuscript, entitled Sunlight for better or for worse?. One version with, one without track changes.
Noordwijk, 03-02-2016 Dear Editor, Enclosed you will find our revised manuscript, entitled Sunlight for better or for worse?. One version with, one without track changes. In response to the reviewers constructive
More informationBisphosphonates and other bone agents for breast cancer(review)
Cochrane Database of Systematic Reviews Bisphosphonates and other bone agents for breast cancer (Review) O Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A O Carrigan B, Wong MHF, Willson
More informationPredicted 25-hydroxyvitamin D Score and Risk of Multiple Sclerosis in U.S. Women
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses Dissertations and Theses 2015 Predicted 25-hydroxyvitamin D Score and Risk of Multiple Sclerosis in U.S. Women Alexandra Purdue-Smithe
More informationThe COSMOS Trial. (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH
COSMOS Trial The COSMOS Trial (COcoa Supplement and Multivitamins Outcomes Study) JoAnn E. Manson, MD, DrPH Howard D. Sesso, ScD, MPH Brigham and Women's Hospital Harvard Medical School Garnet L. Anderson,
More informationThe Role of Observational Studies. Edward Giovannucci, MD, ScD Departments of Nutrition and Epidemiology
The Role of Observational Studies Edward Giovannucci, MD, ScD Departments of Nutrition and Epidemiology Disclosure Information As required, I would like to report that I have no financial relationships
More informationPre-Diagnostic Plasma 25-Hydroxyvitamin D Levels and Risk of Non-Melanoma Skin Cancer in Women
Pre-Diagnostic Plasma 25-Hydroxyvitamin D Levels and Risk of Non-Melanoma Skin Cancer in Women The Harvard community has made this article openly available. Please share how this access benefits you. Your
More informationVITAMIN D THE ICEBERG UNDER THE SURFACE. Robert P. Heaney, M.D., F.A.C.P. Creighton University Osteoporosis Research Center
VITAMIN D THE ICEBERG UNDER THE SURFACE Robert P. Heaney, M.D., F.A.C.P. Creighton University Osteoporosis Research Center DISCLOSURES Robert P. Heaney, M.D. no personal financial relationships to disclose
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationGATE: Graphic Appraisal Tool for Epidemiology picture, 2 formulas & 3 acronyms
GATE: Graphic Appraisal Tool for Epidemiology 1991-2015 1 picture, 2 formulas & 3 acronyms 1 GATE: Graphic Appraisal Tool for Epidemiology Graphic Architectural Tool for Epidemiology Graphic Approach To
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationDoes Photoprotection Lower the Risk for Skin Cancer?
Does Photoprotection Lower the Risk for Skin Cancer? Henry W. Lim, MD Chair Emeritus, Department of Dermatology Senior Vice President for Academic Affairs Henry Ford Hospital, Detroit, Michigan Disclosure
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationIMPORTANT REMINDER DESCRIPTION
Medical Policy Manual Laboratory, Policy No. 52 Vitamin D Testing Next Review: October 2018 Last Review: March 2018 Effective: April 1, 2018 IMPORTANT REMINDER Medical Policies are developed to provide
More information